Page 256 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

212 MEDICAMENTSINDUISANTDES MODIFICATIONS COVALENTESDE L'ADN

WANG Y. et al., Alternative syntheses of the antitumour drug temozolomide avoiding the
use of methyl isocyanate, J. Chem. Soc; Chem. Comm., 1994, 1687-1688.
WANG Y. et al., Antitumour imidazotetrazines. 33. New syntheses of the antitumour drug
temozolomide using « masked » methylisocyanates, J. Chem. Soc. Perkin Trans. 1,
1995, 2783-2787.
WANG Y. et al., Antitumour imidazotetrazines. 35. New synthetic routes to the antitumor
drug temozolomide, J. Org. Chem., 1997, 62, 7288-7294.
WANG Y. et al., Antitumour imidazotetrazines. Part 36. Conversion of 5-aminoimidazole-
4-carboxamide to imidazo[5,1-d][1,2,3,5]tetrazin-4(3/)-ones and imidazo[5,1-
a][1,3,5]triazin-4(3/-l)-ones related in structure to the antitumour agents temozolomide
and mitozolomide,J. Chem. Soc. Perkin Trans. I, 1998, 1669-1675.
AVALOS M. et al., Reactions of 2-amino-2-thiazolines with isocyanates and isothiocya-
nates. Chemical and computational studies on the regioselectivity, adduct rearrange-
ment and mechanistic pathways, J. Org. Chem., 2000, 65, 8882-8892.

CARACTÉRISTIQUES PHYSICOCHIMIQUES
LOWE P. R. et al., Antitumour imidazotetrazines. Part 5. Crystal and molecular structure
of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-4(3/)-one (mitozolomide), J.
Chem. Soc. Perkin. Trans. II, 1985, 357-361.
LOWE P. R et al., Antitumour imidazotetrazines. Part 25. Crystal structure of 8-carba-
moyl-3-methyl[5,1-d]-1,2,3,5-4(3/)-one (temozolomide) and structural comparisons
with the related drugs mitozolomide and DTIC, J. Med. Chem., 1992, 35, 3377-3382.
WHEELHOUSE R. T., Antitumour imidazotetrazines. part 31. The synthesis of isotopically
labelled temozolomide and a multinuclear (H, 1%ç , 5N) magnetic resonance investi-
gation of temozolomide and mitozolomide., J. Chem. Soc. Perkin. Trans. I, 1995, 249-
252.

PHARMACOCINÉTIQUE
TSANG L.L.L et al., Characterisation of urinary metabolites of temozolomide in human
and mice and evaluation of their cytotoxicity, Cancer Chemother. Pharmacol., 1990,
26, 429-439.
ARTEMOV D. et al., Pharmacokinetics of the '?C labeled anticancer agent temozolomide
detected in vivo by selective cross-polarization transfer, Magnetic Reson. Med., 1995,
34, 338-342.
BROCK C.S. et al., The kinetic behaviour of temozolomide in Man, 32th ann. meeting of
the Amer. Soc. Clin Oncology, 1996, 15, 1502.
REIDENBERG P. et al., Effect of food on the oral bioavailability of temozolomide, a new
chemotherapeutic agent, Clin. Pharmacol. Ther., 1996, 59, PIII-44.
REID J.M. et al., Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide
following administration of temozolomide to patients with advanced cancer, Clin. Can-
cer Res., 1997, 3, 2393-2398.
STAKEVITCH P. et al., Effect of ranitidine on the pharmacokinetics of temozolomide,
Clin. Pharmacol. Ther., 1997, 61, PI-39.
AGARWALA S.S. et al., Pharmacokinetic study of temozolomide penetration into CSF in
a patient with durai melanoma, Ann. Oncology, 1998, 9 (supp. 4), 659.